NM 5072
Alternative Names: NM-5072Latest Information Update: 22 May 2024
At a glance
- Originator NovelMed Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Properdin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 22 Apr 2024 NovelMed Therapeutics plans a clinical trial for Paroxysmal nocturnal haemoglobinuria (SC)
- 15 Apr 2024 NM 5072 is available for licensing as of 15 Apr 2024. https://www.novelmed.com/partnersinvestors
- 15 Apr 2024 NM 5072 receives Orphan Drug status for Paroxysmal nocturnal haemoglobinuria in USA